ABSTRACT
Patients undergoing extracorporeal membrane oxygenation (ECMO) are at increased risk of infection. We present the first known report of nosocomial infection with Cupriavidus pauculus attributable to contamination from ECMO equipment and describe the measures taken to halt subsequent infections. A cluster of infections in ECMO patients should prompt team members to consider contamination of equipment with environmental pathogens as a possible cause.
Subject(s)
Cross Infection/microbiology , Equipment Contamination , Extracorporeal Membrane Oxygenation/adverse effects , Gram-Negative Bacterial Infections/etiology , Anti-Bacterial Agents/therapeutic use , Cefepime , Cephalosporins/therapeutic use , Child, Preschool , Ciprofloxacin/therapeutic use , Cross Infection/drug therapy , Cupriavidus , Gentamicins/therapeutic use , Gram-Negative Bacterial Infections/drug therapy , Humans , Infant , Infant, Newborn , Male , Meropenem , Penicillanic Acid/analogs & derivatives , Penicillanic Acid/therapeutic use , Piperacillin/therapeutic use , Tazobactam , Thienamycins/therapeutic useABSTRACT
Human papillomavirus (HPV) infection is the most common sexually transmitted infection among adolescents and adults in the United States. Given the prevalence of this infection and its relationship with the development of cervical cancer, HPV vaccine development has been a major public health initiative in the last decade. Despite extensive research in the development of these vaccines, there remain many unanswered questions in academic and public arenas regarding their administration and role in adolescent medicine.
Subject(s)
Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/therapeutic use , Vaccination , Child , Female , Humans , Papillomavirus Infections/immunology , Papillomavirus Vaccines/immunology , Parents , Vaccination/ethicsABSTRACT
BACKGROUND: Bacterial infections cause significant morbidity and mortality in cardiac transplant patients. Because Streptococcus pneumoniae is the most prominent bacterial pathogen of childhood, the objective of this study was to define the role of S. pneumoniae as a pathogen in the cardiac transplant population. METHODS: Medical records of cardiac transplant patients from March, 1990, through November, 2000, were reviewed to identify invasive pneumococcal infections after transplantation. Demographic, clinical and microbiologic data were reviewed. RESULTS: Nine (11%) of 80 patients had 12 episodes of pneumococcal bacteremia for an incidence rate of 39 cases/1,000 patient years. Patients who were African-American, transplanted before 2 years of age and transplanted because of idiopathic dilated cardiomyopathy were at increased risk of invasive pneumococcal disease (P < 0.05). Six patients were eligible for the 23-valent pneumococcal polysaccharide vaccine before their first invasive infection, but only 1 had received it at the recommended age. Most isolates (82%) were penicillin-susceptible, and no single serotype predominated. There were 2 deaths in the study group, but each was unrelated to infection. Three patients (33%) had recurrent invasive disease with a second serotype an average of 12 months after the first infection. CONCLUSIONS: The incidence of pneumococcal bacteremia in cardiac transplant patients is higher than in the general pediatric population. Risks for infection were being African-American, being younger than 2 years at the time of transplant and being transplanted because of idiopathic cardiomyopathy. It is plausible that pneumococcal vaccine would decrease this risk.